Intrathecal baclofen pump for severe hypertonia in a patient with juvenile Huntington’s disease: illustrative case Authors: Graham M. Winston, Parsa Nilchian, Jeffrey P. Greenfield, Dara Jones Published: 2024 ABSTRACT BACKGROUNDWhile the symptoms of Huntington’s disease (HD) typically first appear around the age of 40 years, 5%–10% of patients experience symptoms before the age of 21 years, in which case it is classified as juvenile Huntington’s disease (JHD). JHD poses a unique clinical problem, as affected patients experience rapid deterioration in their quality of life as the motor manifestations of the disease become overwhelming. Medical treatment options for HD are sparse, and the only Food and Drug Administration–approved medication for the treatment of HD is the VMAT-2 inhibitor tetrabenazine. Unfortunately, treatments for JHD are even more limited, as investigational new drugs for HD oftentimes exclude patients with JHD from trials.OBSERVATIONSHere, the authors present the case of a 15-year-old male with severe hypertonia and dystonic events secondary to JHD that was successfully treated with an intrathecal baclofen (ITB) pump. The patient experienced an improvement in hypertonia and a reduction in the frequency of dystonic events after ITB pump implantation, resulting in overall improved patient comfort.LESSONSThis case highlights the potential benefits of ITB therapy in managing debilitating hypertonia-type symptoms in patients with JHD. Given the limited treatment options for JHD, this intervention has the potential to profoundly enhance the quality of life for affected individuals. https://thejns.org/doi/10.3171/CASE24512 Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric disturbances.1 The prevalence of HD is thought to be approximately 10 in 100,000 persons.2 Inherited cytosine-adenine-guanine (CAG) trinucleotide repeats in the gene encoding for Huntingtin protein are responsible for the development of the disease. While the exact mechanism of neurotoxicity remains to be fully elucidated, misfolded Huntingtin protein aggregates appear to be responsible for pathogenesis, whether via mitochondrial dysfunction, transcriptional dysregulation, impaired synaptic plasticity, or defective axonal transport or more likely via some combination of mechanisms.3 While the symptoms of HD typically first appear around the age of 40 years, it presents before the age of 21 years in 5%–10% of cases, in which case it is classified as juvenile Huntington’s disease (JHD).4, 5 The age of onset of HD is inversely related to the number of CAG repeats. Therefore, it is not surprising that, while it only takes 40 repeats for the disease to be fully penetrant in a patient, the average number of repeats in patients with JHD is approximately 56.5 The motor and neuropsychiatric manifestations of the disease differ between JHD and HD as well. While HD presentation is classically associated with involuntary jerking-type, “chorea” movements, patients with JHD can experience either hyper- or hypokinetic movement, characterized by rigidity, bradykinesia, and parkinsonism.6 Patients with JHD also have a higher incidence of epilepsy.6 Unfortunately, few treatment options exist for patients with HD or JHD. Multidisciplinary support is a mainstay of treatment, including but not limited to physical and occupational therapy, speech therapy, psychiatry, and nursing care.7 Medical treatment options are sparse, and while different pharmaceutical classes, such as antipsychotics and benzodiazepines, have been trialed, the only Food and Drug Administration–approved medication for treatment of HD is the VMAT-2 inhibitor tetrabenazine.8, 9 Treatments for JHD are even more limited, as investigational new drugs for HD oftentimes exclude patients with JHD from trials. Here, we present the case of a 15-year-old male with severe hypertonia and dystonic events secondary to JHD that was successfully treated with an intrathecal baclofen (ITB) pump. Illustrative Case A 15-year-old male presented with genetically confirmed JHD. The patient was adopted, and no medical history was known about his biological parents. While the patient began having behavioral and motor regression starting at age 6 years, he was not diagnosed with JHD until the age of 14 years, when genetic testing revealed 81 CAG repeats. He began experiencing seizures around this time, which became increasingly difficult to control. His motor symptoms manifested as dystonia, rigidity, myoclonus, and parkinsonian gait, for which he was started on levodopa-carbidopa. Eventually, by the age of 15 years, oral baclofen and diazepam were added to his treatment regimen. His disease progressed, and he presented to the hospital in hypertonic crisis, with severe, painful spasms, dystonia, and rigidity refractory to rescue medication (intravenous [IV] administration of lorazepam, diazepam, and morphine), eventually requiring dexmedetomidine drip. At the time of presentation, these episodes had been increasing in frequency, from 1 every 2–3 days to 1–2 daily, each lasting approximately 1 hour on average, though occasionally longer. His full Hypertonia Assessment Tool (HAT) score is documented in Table 1. He was therapeutically maximized on oral baclofen, valium, gabapentin, tizanidine, dantrolene, and artane. Additionally, morphine and valium were used as needed during active crises. Deep brain stimulation device implantation was considered; however, given the extent of basal ganglia degeneration, an ITB pump was instead recommended. Neurosurgery was consulted for an ITB trial after dystonic crises continued to progress. These crises remained unresponsive to medication management. TABLE 1.HAT scoreHAT ItemScoreType of Hypertonia1. Increased involuntary movements/postures of the designated limb w/tactile stimulus of another body part1Dystonia2. Increased involuntary movements/postures w/ purposeful movements of another body part1Dystonia3. Velocity dependent resistance to stretch0Spasticity4. Presence of a spastic catch0Spasticity5. Equal resistance to passive stretch during bidirectional movement of a joint1Rigidity6. Increased tone w/ movement of another body part1Dystonia7. Maintenance of limb position after passive movements0RigidityHAT diagnosis: mixed dystonia (3) and rigidity (1). TABLE 1.HAT scoreHAT ItemScoreType of Hypertonia1. Increased involuntary movements/postures of the designated limb w/tactile stimulus of another body part1Dystonia2. Increased involuntary movements/postures w/ purposeful movements of another body part1Dystonia3. Velocity dependent resistance to stretch0Spasticity4. Presence of a spastic catch0Spasticity5. Equal resistance to passive stretch during bidirectional movement of a joint1Rigidity6. Increased tone w/ movement of another body part1Dystonia7. Maintenance of limb position after passive movements0RigidityHAT diagnosis: mixed dystonia (3) and rigidity (1). HAT score HAT diagnosis: mixed dystonia (3) and rigidity (1). The patient underwent a trial of ITB via lumbar puncture, which provided temporary relief of rigidity and dystonia without adverse effects, as evidenced by improvements in the range of motion of his bilateral lower extremities. Within 48 hours of the trial, he underwent surgical placement of an implantable ITB pump (Medtronic SynchroMed II). An incision was made over the L4–5 level before cautery-assisted dissection to the lumbosacral fascia. After the placement of a 16-gauge Tuohy needle, a catheter was placed into the intrathecal space. The catheter was tunneled subcutaneously and connected to the ITB pump, which was implanted in the right lower quadrant of the abdominal subfascial tissue. There were no surgical complications. The initial baclofen dose was 150 µg/day, which was titrated to 972.1 µg/day over a period of 2 months (36 µg/hr basal with 30 µg bolus every 6 hours at 03:00, 09:00, 15:00, and 21:00) to optimize symptom control. Considering the patient’s rapid deterioration, an expedited titration schedule was followed, increasing the ITB pump dose every 48 hours as opposed to every 72 hours. Postoperatively, his resting posture improved per physiatry assessments, as detailed in Table 2. He also had a decreased frequency of hypertonic crises, subjective improvement in pain as evidenced by decreased grimacing, and reduced overall need for sedation. A full summary of the patient’s medication changes is detailed in Table 3. While the surgery was uneventful and the patient was extubated successfully postoperatively, his postoperative course was complicated by seizures, poor nutritional intake, and aspiration pneumonia. Despite these challenges, the patient was successfully discharged from the hospital without the requirement for a ventilator, although on high-level bilevel positive airway pressure, on hospital day 133, postoperative day 120. Since discharge, his disease has continued to progress and he has experienced numerous respiratory and infectious complications, eventually requiring gastrostomy, tracheostomy, and ventilatory support. Despite this, however, at his 18-month office visit, he continues to derive benefits from his ITB pump placement. TABLE 2.Pre- and post-ITB pump assessmentRegionResting Posture Pre-ITB pumpResting Posture Post-ITB pumpShoulderBilat: 160° abductionUnchangedElbowsBilat: 160° flexion, lacks full extension, unable to fully assess end range of motion due to rigidityLt: able to fully extend elbow passively Rt: 20° flexion contractureWristBilat: flexed 60°, lacks full extensionLt: flexed 30°, able to passively extendRt: full passive extensionHipsBilat: abducted and externally rotated 80°Lt: flexed 60°, rigid, no passive extensionRt: flexed 110°, rigid no passive extensionLt: abducted 45°Rt: extended to 90°KneesBilat: flexed 70–90°, no passive extensionLt: 70° knee flexion, 20° from full extensionRt: 90° knee flexion, no passive extensionFeetBilat: equinovarusBilat: equinovarus TABLE 3.Medication summary: daily doses recordedMedicationPre-ITB pump1 Mo2 Mos3 Mos4 MosBaclofen PO (mg)909010100Carbidopa-levodopa PO (mg)150–600150–600150–600150–600150–600Diazepam PO & IV (mg)2220203030Gabapentin (mg)9001200140014001400Dexmedetomidine (µg/kg/hr)1.40.6000Levetiracetam (mg)30003000300030003000Tizanidine (mg)88888Trihexyphenidyl (mg)1014141414Valproate (mg)15001200200030003000Clonazepam (mg)000.533Lamictal (mg)00400400400Quetiapine (mg)0001000Lorazepam (mg)00004PO = by mouth. TABLE 2.Pre- and post-ITB pump assessmentRegionResting Posture Pre-ITB pumpResting Posture Post-ITB pumpShoulderBilat: 160° abductionUnchangedElbowsBilat: 160° flexion, lacks full extension, unable to fully assess end range of motion due to rigidityLt: able to fully extend elbow passively Rt: 20° flexion contractureWristBilat: flexed 60°, lacks full extensionLt: flexed 30°, able to passively extendRt: full passive extensionHipsBilat: abducted and externally rotated 80°Lt: flexed 60°, rigid, no passive extensionRt: flexed 110°, rigid no passive extensionLt: abducted 45°Rt: extended to 90°KneesBilat: flexed 70–90°, no passive extensionLt: 70° knee flexion, 20° from full extensionRt: 90° knee flexion, no passive extensionFeetBilat: equinovarusBilat: equinovarus Pre- and post-ITB pump assessment TABLE 3.Medication summary: daily doses recordedMedicationPre-ITB pump1 Mo2 Mos3 Mos4 MosBaclofen PO (mg)909010100Carbidopa-levodopa PO (mg)150–600150–600150–600150–600150–600Diazepam PO & IV (mg)2220203030Gabapentin (mg)9001200140014001400Dexmedetomidine (µg/kg/hr)1.40.6000Levetiracetam (mg)30003000300030003000Tizanidine (mg)88888Trihexyphenidyl (mg)1014141414Valproate (mg)15001200200030003000Clonazepam (mg)000.533Lamictal (mg)00400400400Quetiapine (mg)0001000Lorazepam (mg)00004PO = by mouth. Medication summary: daily doses recorded PO = by mouth. Informed Consent The necessary informed consent was obtained in this study. Discussion Observations Here, we present a single case of a patient with debilitating hypertonia secondary to JHD, with improvement after the implantation of an ITB pump. JHD is a devastating disease, with little to no treatment options available for symptom management or to prevent disease progression. To our knowledge, this is the first reported case utilizing a baclofen pump for the management of HD symptoms in either adult or juvenile patients. The ITB pump has been demonstrated to be safe and efficacious in the pediatric population for other pathologies causing dystonia, most commonly in patients with cerebral palsy or posttraumatic brain or spinal cord injury.10–13 Baclofen functions by reducing the hyperexcitability of neurons through its action as a gamma-aminobutyric acid B receptor agonist, in turn reducing involuntary muscle movement in the brain and spinal cord.14 It is also thought to serve as an inhibitory ligand, impairing the release of excitatory neurotransmitters before synaptic transmission.15 These mechanisms make baclofen a biologically feasible treatment option for HD, as degeneration of medium spiny GABAergic neurons in the striatum is considered a neuropathological hallmark of the disease.16, 17 Although preclinical studies have shown promise for baclofen,17 its clinical effectiveness in HD has been limited. Randomized controlled trials employing oral baclofen in early HD failed to prevent disease progression or improve symptoms.18 Lessons In conclusion, we have presented the case of a 15-year-old male with JHD who experienced significant improvement in debilitating hypertonia following the placement of an ITB pump. Given the limited treatment options for JHD, this intervention has the potential to profoundly enhance the quality of life for affected individuals. While clinical studies have shown limited success in disease modification with oral baclofen in HD, our case highlights the potential therapeutic value of ITB administration for symptom management in patients with JHD. Further research and larger-scale clinical trials, however, are warranted to explore the full potential of this treatment modality in the management of HD and JHD. Acknowledgments We acknowledge all the providers and staff who assisted in taking care of our patient. Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Author Contributions Conception and design: all authors. Acquisition of data: Winston, Greenfield, Jones. Analysis and interpretation of data: Winston, Nilchian, Jones. Drafting the article: all authors. Critically revising the article: all authors. Reviewed submitted version of manuscript: Winston, Nilchian, Jones. Approved the final version of the manuscript on behalf of all authors: Winston. Statistical analysis: Jones. Administrative/technical/material support: Winston, Jones. Study supervision: Winston, Greenfield, Jones. Correspondence Graham M. Winston: Weill-Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY. gmw2002@med.cornell.edu.